Phase 1 trial of COVID-19 vaccine successful,reports China

▴ phase-1-trial-of-covid19-vaccine-successfulreports-china
China says Phase 1 vaccine trial successful on humans

The first COVID-19 vaccine to reach phase I clinical trial is safe, well-tolerated, and capable of generating an immune response against the novel coronavirus in humans, says new research published in The Lancet.

According to the study of 108 adults, the vaccine produced neutralising antibodies, and a response mediated by the immune system’s T-cells against the novel coronavirus, SARS-CoV-2.

However, the scientists, including those from the Beijing Institute of Biotechnology in China said further research is needed to confirm whether the vaccine protects against SARS-COV-2 infection.

In the trial, carried out in 108 healthy adults, the vaccine demonstrated promising results after 28 days, with the final results to be evaluated in six months, the study said.

“These results represent an important milestone. The trial demonstrates that a single dose of the new adenovirus type 5 vectored COVID-19 (Ad5-nCoV) vaccine produces virus-specific antibodies and T cells in 14 days,” said study co-author Wei Chen from the Beijing Institute of Biotechnology.

Based on the results, Chen said the vaccine is a potential candidate for further investigation.

However, the researchers cautioned that the results should be interpreted carefully.

“The challenges in the development of a COVD-19 vaccine are unprecedented, and the ability to trigger these immune responses does not necessarily indicate that the vaccine will protect humans from COVID-19,” Chen explained.

The Ad5 vectored COVID-19 vaccine used in the trial is the first to be tested in humans, the scientists said.

It uses a weakened common cold-causing adenovirus — which infects human cells readily, but is incapable of causing disease — to deliver genetic material that codes for the SARS-CoV-2 spike protein to the cells, the study noted.

The scientists said these cells then produce the spike protein and travel to the lymph nodes where the immune system creates antibodies.

These then recognise the spike protein and fight off the coronavirus, the researchers explained.

In the trial, they assessed the safety and ability of the new Ad5-nCoV vaccine to generate an immune response of different dosages in 108 healthy adults between the ages of 18 and 60 years.

The volunteers were assigned to receive either a single injection of the new Ad5 vaccine at a low dose, middle dose, or a high dose, they said.

According to the study, the volunteers’ blood was checked at regular intervals following vaccination to see whether the vaccine stimulated two parts of the immune system.

These are the body’s ‘humoral response’, which is the part of the immune system that produces antibodies to fight infection, and the ”cell-mediated” arm, which depends on a group of T cells to fight the virus, the scientists said.

They added that an ideal vaccine candidate generates both antibody and T cell responses to defend against SARS-CoV-2.

Based on the results, the researchers said the vaccine was well tolerated by the volunteers at all doses with no serious adverse events reported within 28 days of vaccination.

They said most adverse events were mild or moderate, with 83 per cent of those receiving low and middle doses of the vaccine and 75 per cent in the high dose group reporting at least one adverse reaction within seven days of vaccination.

These reactions were mild pain at the injection site reported in over half of vaccine recipients, fever in 50 per cent of them, fatigue, headache, and muscle pain as well.

Within two weeks of vaccination, the study noted that all dose levels of the vaccine triggered some level of immune response.

Some of the participants, the researchers said, also exhibited a form of neutralising antibodies against SARS-CoV-2.

After 28 days, they said most participants had a four-fold increase in binding antibodies.

The scientists also added that 50 per cent of the participants in the low- and middle-dose groups, and three-quarters of those in the high-dose group showed neutralising antibodies against SARS-CoV-2.

In the majority of volunteers, they said the vaccine also stimulated a rapid T cell response.

On further analyses, the researchers said the majority of recipients showed either a positive T cell response or had detectable neutralising antibodies against SARS-CoV-2 as much as 28 days after vaccination.

However, they said high pre-existing immunity to adenovirus type 5 — the common cold virus vector used in the study, may have reduced both the antibody and T-cell response in the participants.

“Our study found that pre-existing Ad5 immunity could slow down the rapid immune responses to SARS-CoV-2 and also lower the peaking level of the responses,” said Feng-Cai Zhu from the Jiangsu Provincial Center for Disease Control and Prevention in China, who led the study.

Citing the main limitations of the trial, the authors said the study had a small sample size and was conducted in a relatively short duration, with a lack of randomised control group.

They said further research will be needed before this trial vaccine becomes available to all.

Recently for the first time, since China started coming out with overwhelming numbers in January, recorded no fresh coronavirus infections on Saturday, on the following day after Communist Party leaders celebrated "major achievements" in the virus fight.

The virus emerged in the Chinese city of Wuhan late last year, cases and fatalities peaked in mid-February but the neighbouring country has brought spread of the virus under control.

However, China’s death tally 4634 against a population of 1.4 billion people is far below the number of fatalities in much smaller countries.

The world doubts the reliability of the numbers China has purported. United States questions on how much information Beijing has shared with the international community.

The milestone comes a day after the opening of China's rubber-stamp parliament, the National People's Congress, where Premier Li Keqiang said the country had "made major strategic achievements in our response to COVID-19."

However, he warned that the country still faced "immense" challenges.

Authorities in Wuhan have come under attack for reprimanding and silencing doctors who first raised the alarm about the virus late last year, and repeated changes to counting methodology have cast further doubt over China's official data.

Source :PTI

Tags : #Phase1Trial #SARS-COV-2 #BeijingInstituteofBiology #China

About the Author


Team Medicircle

Related Stories

Loading Please wait...
-Advertisements-


Trending Now

India's coronavirus cases rise to 5.2 million with 96,424 new infections and 87,472 recoveriesSeptember 19, 2020
UV light can kill Covid with our harming human : American Journal of Infection controlSeptember 19, 2020
Israel imposes second coronavirus lockdown during high holidaysSeptember 19, 2020
British DnaNudge coronavirus test is accurate : UK MHRASeptember 19, 2020
Uttar Pradesh conducts 1,50,000 tests per day while NCL donates 50 ambulances September 19, 2020
Male pattern baldness or Alopecia : What you should know September 18, 2020
Huntington Study Group partners with Prilenia Therapeutics : Phase 3 Clinical Study of Pridopidine September 18, 2020
Alarming rates of transmission of virus in EuropeSeptember 18, 2020
China Biopharma plant leak infects thousands with bacterial diseaseSeptember 18, 2020
WHO urges safety for health workers bearing brunt of CoronavirusSeptember 18, 2020
Moderna to seek COVID vaccine's limited emergency useSeptember 18, 2020
Gujarat reports record 1379 new cases of COVID-19 in last 24 hoursSeptember 18, 2020
Global Coronavirus cases surpass 30 MillionSeptember 18, 2020
Karnataka reports 9366 new COVID-19 positive cases in last 24 hoursSeptember 18, 2020
Pulmonary Arterial Hypertension treatment : Moderna and Chiesi Group collaboratesSeptember 18, 2020
Sero survey begins in Chhattisgarh amid rising COVID-19 casesSeptember 18, 2020
WHO calls for protective equipments for frontline medical workersSeptember 18, 2020
Around 15 thousand Railway employees affected by Corona virusSeptember 18, 2020
Elicio Therapeutics collaborates with Moffitt Cancer CenterSeptember 18, 2020
NGO from Maharashtra filed a PIL on COVID-19 drugsSeptember 18, 2020